Cyclothymic and hyperthymic temperaments in depressive patients: supportive evidence for bipolar ii1/2 and iv3

被引：0
|
作者：
Araki, Y. [1 ]
机构：
[1] Oita Univ, Fac Med, Dept Neuropsychiat, Oita 87011, Japan
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2010年 / 20卷
关键词：
D O I：
10.1016/S0924-977X(10)70467-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S339 / S340
页数：2
相关论文
共 4 条
  • [1] Cyclothymic and hyperthymic temperaments may predict bipolarity in major depressive disorder: A supportive evidence for bipolar II1/2 and IV
    Goto, Shinjiro
    Terao, Takeshi
    Hoaki, Nobuhiko
    Wang, Yumei
    JOURNAL OF AFFECTIVE DISORDERS, 2011, 129 (1-3) : 34 - 38
  • [2] The high prevalence of bipolar II and associated cyclothymic and hyperthymic temperaments in HIV-patients
    Perretta, P
    Akiskal, HS
    Nisita, C
    Lorenzetti, C
    Zaccagnini, E
    Della Santa, M
    Cassano, GB
    JOURNAL OF AFFECTIVE DISORDERS, 1998, 50 (2-3) : 215 - 224
  • [3] An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicullar Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis
    Ardeshna, Kirit M.
    Qian, Wendi
    Smith, Paul
    Warden, June
    Stevens, Lindsay
    Pocock, Christopher F. E.
    Miall, Fiona
    Cunningham, David
    Davies, John
    Walewski, Jan
    Ferhanoglu, A. Burhan
    Bradstock, Ken
    Linch, David C.
    BLOOD, 2010, 116 (21) : 5 - 5
  • [4] Patients with PD-L1 expression by IHC 1/2/3 demonstrated evidence of increased activity. Durable responses were observed in mRCC patients, warranting further study Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (mRCC)
    Motzer, R.
    Rini, B.
    Mcdermott, D.
    Redman, B.
    Kuzel, T.
    Harrison, M.
    Vaishampayan, U.
    Drabkin, H.
    George, S.
    Logan, T.
    Margolin, K.
    Plimack, E. R.
    Waxman, I.
    Lambert, A.
    Hammers, H.
    BJU INTERNATIONAL, 2014, 114 : 12 - 12
1